Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 8/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5223815 | 0.98 | ADRB1 (0.63) | ADRB1DRD2HTR2ADRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5365168 | 0.98 | ADRB1 (0.63) | ADRB1DRD2HTR2ADRD3SIGMAR1 | |
| SCHEMBL3610680 | 0.94 | ADRB1 (0.58) | ADRB1DRD2HTR2ADRD3SIGMAR1 | |
| SCHEMBL3615477 | 0.91 | ADRB1 (0.61) | ADRB1DRD2HTR2ADRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5362928 | 0.89 | ADRB1 (0.60) | ADRB1DRD2HTR2ADRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5218353 | 0.89 | ADRB1 (0.60) | ADRB1DRD2HTR2ADRD3SIGMAR1 | |
| SCHEMBL4948654 | 0.89 | ADRB1 (0.60) | ADRB1DRD2HTR2ADRD3SIGMAR1 | |
| SCHEMBL3605703 | 0.87 | ADRB1 (0.57) | ADRB1DRD2HTR2ADRD3SIGMAR1 | |
| SCHEMBL8912824 | 0.83 | ADRA1D (0.50) | ADRB1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL9049827 | 0.82 | DRD2 (0.54) | DRD2HTR2ADRD3DRD1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368115-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHUJING BIOPHARMA CO., LTD (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4382521-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shujing Biopharma Co., Ltd (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-117769545-A | Tri-fused ring derivative-containing regulator, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023011608-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2023011608-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | DONSBACH, MARTIN (DE) | 2010-07-01 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2137185-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | Gmeiner, Dr. Peter (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113559-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | SCHWARZ PHARMA AG (DE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | disclosed |
| US-6140331-A | FOR TREATING ANXIETY DISORDERS, DEPRESSION, PSYCHOSIS, IMPULSE CONTROL DISORDERS, ALCOHOL ABUSE, ISCHAEMIC DISEASES, CARDIOVASCULAR DISORDERS, SIDE EFFECTS INDUCED BY CONVENTIONAL ANTIPSYCHOTIC AGENTS AND SENILE DEMENTIA | H. LUNDBECK A/S (DK) | 2000-10-31 | — | — | US | disclosed |
| EP-0673375-B1 | FUSED BENZO COMPOUNDS | LUNDBECK & CO AS H (DK) | 1999-02-24 | — | — | EP | disclosed |
| US-5753661-A | TREATMENT OF NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | H. LUNDBECK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| US-5605896-A | Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1997-02-25 | — | — | US | disclosed |
| EP-0673375-A1 | FUSED BENZO COMPOUNDS | H. LUNDBECK A/S (DK) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013659-A1 | FUSED BENZO COMPOUNDS | H. LUNDBECK A/S (DK) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | INMT, AANAT, AZI2 | ADRB1 370/4885DRD2 123/4885HTR2A 24/4885 |
| US-20240368115-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TPH1, TPH2, GAP43 | ADRB1 10/4885DRD2 327/4885HTR2A 57/4885 |
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | ADRB1 28/4885DRD2 163/4885HTR2A 8/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | ADRB1 456/4885DRD2 242/4885HTR2A 5/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | ADRB1 28/4885DRD2 85/4885HTR2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.